priors.science/reviews/novel-antibiotics

Novel Antibiotics

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked

Weeklyre-scored against new papers

3 Established · 8 Likely · 5 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableAMR causes over one million deaths annuallyAmr BurdenEstablished94%—

StableDalbavancin achieves high cure rates in acute bacterial skin infectionsLipoglycopeptidesEstablished91%—

StableStewardship reduces consumptionStewardshipEstablished88%—

StableCAZ-AVI achieves clinical cure in most serious CRE infectionsCaz AviLikely74%—

StableCeftolozane-tazobactam is effective for DTR Pseudomonas aeruginosa infectionsCeft TazoLikely73%—

StableCRE bacteraemia carries 30 to 45 percent 30-day mortalityAmr BurdenLikely72%—

StableCAZ-AVI reduces mortality in KPC CRE infections versus older agentsCaz AviLikely71%—

StableLipoglycopeptides reduce length of stayLipoglycopeptidesLikely70%—

StableStewardship programmes reduce multidrug-resistant organism rates in hospitalsStewardshipLikely69%—

StableCefiderocol achieves high cure rates in non-Acinetobacter resistant infectionsCefiderocolLikely68%—

StableCAZ-AVI plus aztreonam is effective against MBL-producing organismsCaz AviLikely67%—

StableDalbavancin osteomyelitis efficacyLipoglycopeptidesUncertain62%—

StablePhage therapy improves clinical outcomes in drug-resistant bacterial infectionsPhageUncertain54%—

StableCeftolozane-tazobactam resistance emergence exceeds CAZ-AVI during treatmentCeft TazoUncertain52%—

StableCefiderocol has excess mortality risk in Acinetobacter baumannii infectionsCefiderocolUncertain51%—

StablePhage antibiotic combinationPhageUncertain50%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic